How many drugs treat Seborrheic Dermatitis?

Drug Landscape tracks 10 marketed treatments for Seborrheic Dermatitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Seborrheic Dermatitis?

Most recent: Topicort — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/seborrheic-dermatitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Seborrheic Dermatitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Seborrheic Dermatitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Seborrheic Dermatitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Flonase	fluticasone propionate	GSK (GlaxoSmithKline)	Inhaled/intranasal corticosteroid	Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor	1994-11-04
Dermatop	PREDNICARBATE	Bausch Health	Corticosteroid	Glucocorticoid receptor	1991-01-01
Ultravate	ulobetasol propionate	Ranbaxy	ulobetasol propionate	Glucocorticoid receptor	1990-01-01
Elocon	MOMETASONE FUROATE	Merck & Co.	Corticosteroid	Progesterone receptor	1987-01-01
Lac-Hydrin	AMMONIUM LACTATE	Sun Pharma	alpha-Hydroxy Acid [EPC]		1985-01-01
Temovate	CLOBETASOL PROPIONATE	Fougera Pharms	Corticosteroid	Glucocorticoid receptor	1985-01-01
Benzamycin	BENZOYL PEROXIDE	Mayne Pharma	benzoyl peroxide		1984-01-01
Loprox	CICLOPIROX	Bausch Health	ciclopirox	Poly [ADP-ribose] polymerase 1	1982-01-01
Nizoral	ketoconazole	Johnson & Johnson (Janssen)	Azole Antifungal [EPC]	Aldehyde oxidase, Cytochrome P450 21, Sodium/nucleoside cotransporter 1	1981-06-26
Cyclocort	AMCINONIDE	Astellas Pharma	Corticosteroid [EPC]	Glucocorticoid receptor	1979-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-16 — Topicort · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 14 drugs in Seborrheic Dermatitis
Merck & Co. · 3 drugs in Seborrheic Dermatitis
Sun Pharma · 2 drugs in Seborrheic Dermatitis
Bausch Health · 2 drugs in Seborrheic Dermatitis
GSK (GlaxoSmithKline) · 1 drug in Seborrheic Dermatitis
Chattem · 1 drug in Seborrheic Dermatitis
Aier School of Ophthalmology, Central South University · 1 drug in Seborrheic Dermatitis
Fougera Pharms · 1 drug in Seborrheic Dermatitis
Astellas Pharma · 1 drug in Seborrheic Dermatitis
Fougera Pharms Inc · 1 drug in Seborrheic Dermatitis
Eurofarma · 1 drug in Seborrheic Dermatitis
Creighton University · 1 drug in Seborrheic Dermatitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Seborrheic Dermatitis:

Cite this brief

Drug Landscape (2026). Seborrheic Dermatitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/seborrheic-dermatitis. Accessed 2026-06-10.

Seborrheic Dermatitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing